New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II ...

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced plans to raise $10 million through a private placement, leading to a significant drop in its share price [1] - Following the announcement, shares of Intelligent Bio fell 19.7% to $7.65 [1] Stock Movements - Lavoro Limited (NASDAQ:LVRO) saw a substantial increase of 181%, reaching $1.2900 [4] - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 57.7% to $5.32 after issuing FY26 guidance, expecting US net sales of Linzess to be between $1.125 billion and $1.175 billion [4] - Brand Engagement Network, Inc. (NASDAQ:BNAI) jumped 56% to $3.6290 after entering a Vendor Services Project Agreement with a global advertising agency [4] - ChowChow Cloud International Holdings Limited (NYSE:CHOW) increased by 39.7% to $0.8500 due to year-over-year revenue and net income growth in H1 2025 [4] - Sidus Space, Inc. (NASDAQ:SIDU) gained 29% to $4.0314, marking a 470% surge over the past month [4] - Baidu, Inc. (NASDAQ:BIDU) rose 12.1% to $146.57 after announcing a proposed spin-off and Hong Kong listing of its AI unit [4] Declines - Outlook Therapeutics, Inc. (NASDAQ:OTLK) experienced a significant decline of 58% to $0.6632 after receiving a complete response letter from the FDA regarding its biologics license application [4] - ESH Acquisition Corp. (NASDAQ:ESHA) fell 23.5% to $14.68 [4] - Nuvve Holding Corp. (NASDAQ:NVVE) declined 15.3% to $2.1500 after announcing the closing of a private placement [4]

Group 1 - The article reports significant declines in the stock prices of several Chinese concept stocks, with notable drops including Wokai Medical down 32.92% and BitVentures down 21.57% [1] - The closing prices and trading volumes for the affected stocks are detailed, highlighting Wokai Medical's latest price at 0.0328 with a trading volume of 2.8645 million, and BitVentures at 1.200 with a trading volume of 0.5128 million [1] - Other companies experiencing declines include Dongfang Culture down 13.57%, Tongcheng Tongmei down 13.48%, and Jian Yong Biotechnology down 11.44%, indicating a broader trend of negative performance among these stocks [1]

Group 1 - U.S. stock futures were mostly flat, with Nasdaq 100 futures slipping around 0.01% [1] - Sidus Space, Inc. announced a public offering of 19,230,800 shares at $1.30 per share, leading to a 39.2% decline in its shares to $1.39 in pre-market trading [1] Group 2 - Starfighters Space Inc shares dipped 23.2% to $24.19 after a significant gain of over 370% on Monday [2] - ECD Automotive Design, Inc. fell 15.4% to $0.1650 following a 1-for-5 reverse stock split announcement [2] - CapsoVision Inc dipped 5.6% to $12.35, while Rocket Lab Corp fell 5.3% to $73.46 after a previous 10% jump [2] - Intuitive Machines Inc declined 5.2% to $15.82 despite a price target increase from $14 to $20 by B. Riley Securities [2] - Firefly Aerospace Inc shares declined 4.4% to $27.33 after a 16% increase due to joining the Russell 2000 and Russell 3000 indexes [2] - AST SpaceMobile Inc shares declined 3.1% to $83.82 after a 14% surge related to new satellite details [2]

Group 1 - The core point of the article highlights significant stock price increases for several Chinese concept stocks, with notable gains in their respective closing prices [1] Group 2 - Haoxin Holdings (HXHX) experienced a remarkable increase of 273.91%, closing at 1.2900, with a trading volume of 270 million [1] - Meihua Chuangfu (MGRT) saw a rise of 70.41%, closing at 12.440, with a trading volume of 4.6887 million [1] - Jian Yong Biotechnology (MENS) increased by 50.55%, closing at 4.780, with a trading volume of 124 million [1] - Zhongchi Chefu (AZI) rose by 32.80%, closing at 3.320, with a trading volume of 163 million [1] - Paiming Xincheng (IZM) gained 28.00%, closing at 1.600, with a trading volume of 1.2584 million [1]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 100 points on Monday. The Dow rose by 0.18% to 48,222.17, the NASDAQ increased by 0.56% to 23,439.24, and the S&P 500 gained 0.45% to 6,864.96 [1] - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.81%, Hong Kong's Hang Seng up 0.43%, China's Shanghai Composite rising 0.69%, and India's BSE Sensex increasing by 0.75% [6] Sector Performance - Energy shares rose by 1.3% on Monday, while utilities stocks fell by 0.5% [1] Commodity Prices - Oil prices increased by 2.2% to $57.75, gold rose by 1.7% to $4,463.30, silver was up 2.5% to $69.150, and copper fell by 0.1% to $5.5085 [4] European Market Performance - European shares were lower, with the eurozone's STOXX 600 declining by 0.3%, Spain's IBEX 35 Index falling by 0.2%, London's FTSE 100 down by 0.5%, Germany's DAX 40 decreasing by 0.3%, and France's CAC 40 dropping by 0.5% [5] Notable Stock Movements - Haoxin Holdings Limited (NASDAQ:HXHX) shares surged by 118% to $0.7513, while Sidus Space, Inc. (NASDAQ:SIDU) increased by 78% to $2.0650 after receiving a contract from the Missile Defense Agency [8] - Jyong Biotech Ltd. (NASDAQ:MENS) shares rose by 36% to $4.32 [8] - Luminar Technologies, Inc. (NASDAQ:LAZR) shares dropped by 60% to $0.2396 after announcing voluntary Chapter 11 proceedings [8] - EUDA Health Holdings Limited (NASDAQ:EUDA) shares fell by 25% to $2.09 following a strategic technology integration announcement [8] - Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) shares decreased by 20% to $1.74 as the company announced a self tender offer [8]

Core Viewpoint - Jyong Biotech Ltd. is experiencing fluctuations in its share price and increased trading volume following the expiry of the lock-up period, while engaging with investment funds interested in purchasing its shares [1]. Company Overview - Jyong Biotech Ltd. is a biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with a target market in the U.S., EU, and Asia [6]. - The company has established integrated capabilities across all key functionalities of drug development since its inception in 2002, including drug discovery, clinical trials, and commercialization [6]. Financial and Operational Status - The company's research and development operations remain solid, and its financial condition is consistent with recent public filings, including the Current Report on Form 6-K [3]. - Jyong Biotech has completed four Phase III clinical trials in the U.S. and Taiwan, along with one Phase II clinical trial in Taiwan, and is advancing its investigational pipeline [5]. Strategic Developments - The company holds global multi-country invention patents, providing market protection across the Americas, Asia, and Europe, and has signed Letters of Intent (LOIs) with several international pharmaceutical companies [5]. - Jyong Biotech is committed to expanding its global presence and aims to deliver world-class botanical new drugs to address significant unmet medical needs [5]. Compliance and Disclosure - The company confirms compliance with SEC regulations and is not aware of any material, unpublished price-sensitive information that would explain the recent trading activity [2][4].

Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with notable drops including Jian Yong Biotechnology down 81.04% and Antelope Holdings down 25.73% [1] Group 2 - Jian Yong Biotechnology (MENS) closed at 2.920, experiencing a drop of 81.04%, which translates to a decrease of 12.480, with a trading volume of 13.1486 million [1] - Antelope Holdings (AEHL) closed at 1.790, down 25.73%, reflecting a decline of 0.620, with a trading volume of 0.4457 million [1] - 3 E Network Technology (MASK) saw a decrease of 22.96%, closing at 0.2620, down 0.0781, with a trading volume of 0.7766 million [1] - Token Cat (TC) closed at 12.000, down 21.77%, which is a drop of 3.340, with a trading volume of 1.0489 million [1] - Everbright Digital (EDHL) closed at 0.4515, down 17.49%, reflecting a decrease of 0.0957, with a trading volume of 0.2571 million [1]

Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with CIMG experiencing the largest drop of 31.98% [1] - CIMG's latest price is reported at 1.170, with a decrease of 0.550 and a trading volume of 1.7132 million [1] - Other notable declines include MENS down 31.22% to 15.400, CGTL down 18.63% to 0.952, NCRA down 18.60% to 1.050, and MASK down 17.05% to 0.3401 [1][1][1] Group 2 - The trading volume for MENS was 6.5639 million, while CGTL had a trading volume of 1.1541 million [1] - NCRA's trading volume was 0.4163 million, and MASK's trading volume was 1.8397 million [1][1]

Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding Memorandum of Understanding (MOU) with a Vietnam-based pharmaceutical distribution company to explore the development and commercialization of MCS-2 in the Vietnamese pharmaceutical market [1][2]. Group 1: MOU Details - The MOU outlines that both parties will conduct due diligence and discussions to define the scope and structure of any potential collaboration, including commercial strategy, regulatory pathway, and local market execution [2]. - There is no guarantee that a definitive agreement will be reached or that the collaboration will be finalized [2]. Group 2: Strategic Importance - The CEO of Jyong Biotech emphasized that this MOU is a significant step in the company's Asia-focused strategy to introduce plant-derived MCS therapies to new markets, highlighting Vietnam's potential for patient access and local partnerships [3]. - This MOU follows a previously announced non-binding Letter of Intent with a South Korean pharmaceutical company to explore in-licensing and development opportunities for plant-derived MCS products [3]. Group 3: Product Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [4]. Group 4: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with initial market focus on the U.S., EU, and Asia [5]. - Since its establishment in 2002, the company has developed integrated capabilities across all key drug development functions, including early-stage drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [5].